NCT07503834

"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ (ILIPO)"

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Nantes University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective, open-label, uncontrolled, non-randomized, single-center Phase I/II clinical trial evaluating the safety of Anakinra in the immediate post-transplant period following pancreatic transplantation

Detailed description

Pancreas transplantation is the treatment of choice for curing diabetes by restoring long-term endogenous insulin secretion. However, the increased risk of rejection compared to other transplants, and especially the risk of early graft loss due to immunological thrombosis, are major obstacles to this procedure. IL-1β blockade is commonly used in islet transplantation, as it has demonstrated a benefit in terms of graft survival when administered immediately postoperatively, in combination with TNFα blockade18. The ILIPO study therefore aims to evaluate the safety of anti-IL-1β treatment as an adjunct to the regimen currently used in our department for pancreatic transplants.

Conditions

• Pancreatic Transplant

Interventions

Type	Name	Description
DRUG	Anakinra 100Mg/0.67Ml Inj Syringe	Safety of Anakinra in the immediate aftermath of pancreatic transplantation

Timeline

• Start date: 2026-05-01
• Primary completion: 2028-11-01
• Completion: 2029-11-01
• First posted: 2026-03-31
• Last updated: 2026-03-31

Locations

1 site across 1 country: France